Costs rising, AstraZeneca switches contractors and once again delays scheduled completion of its troubled $650M-plus HQ project
Those rumors about big trouble for AstraZeneca’s $650 million (plus) HQ project proved to be entirely accurate. Today a spokesperson for the pharma giant tells …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
